when is semaglutide off patent expiration us As the patents on semaglutide, a popular diabetes and anti-obesity drug China's weight-loss drug makers take

This article contextualizes the immediate impact on F&B consumption and highlights which opportunity areas to watch as the phenomenon continues to unfold

Secondary efficacy endpoints included proportion of participants achieving body weight loss of 5% or more and 10% or more from baseline to week 24, change from baseline to week 24 in body weight, waist circumference and BMI, change from baseline to week 24 in glucose metabolism parameters (HbA1c, fasting plasma glucose and fasting insulin), changes from baseline to week 24 in cardiovascular risk factors (blood pressure, lipids [total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides]), changes from baseline to week 12 and week 24 in serum uric acid and ALT, changes in IWQOL-Lite scores, as well as changes from baseline to week 36 in body weight, waist circumference, BMI, glucose and cardio-metabolic risk factors

If convenience and needle avoidance matter more to you, sublingual is a reasonable alternative with the understanding that efficacy data is less robust

Nausea is the most frequently reported side effect for individuals starting GLP-1 medications

Why are we still in need of novel anti-obesity medications

It's okay to be the last one eating